Nuvation Bio Inc. Reports Director Changes and Compensation Updates
Ticker: NUVB · Form: 8-K · Filed: Oct 7, 2024 · CIK: 1811063
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Nuvation Bio board shakeup and pay plan changes filed 10/7.
AI Summary
Nuvation Bio Inc. announced on October 7, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory plans.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate internal shifts that may affect future performance or strategic direction.
Key Players & Entities
- Nuvation Bio Inc. (company) — Registrant
- Panacea Acquisition Corp (company) — Former Company Name
FAQ
What specific changes were made to the board of directors?
The filing indicates the departure of certain directors and the election of new ones, though specific names of departing and newly elected directors are not detailed in this summary section.
Were there any changes to executive officers?
Yes, the filing notes the departure of certain officers.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is October 7, 2024.
What is Nuvation Bio Inc.'s principal executive office address?
The principal executive offices are located at 1500 Broadway, Suite 1401, New York, NY 10036.
What was Nuvation Bio Inc.'s former company name?
Nuvation Bio Inc.'s former company name was Panacea Acquisition Corp.
Filing Stats: 880 words · 4 min read · ~3 pages · Grade level 12.5 · Accepted 2024-10-07 16:10:55
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVB The New Yo
- $11.50 — of Common Stock at an exercise price of $11.50 per share NUVB.WS The New York Stoc
- $510,000 — s: (i) an initial annual base salary of $510,000 per year (the "Initial Base Salary"), (
Filing Documents
- d787897d8k.htm (8-K) — 27KB
- 0001193125-24-233794.txt ( ) — 183KB
- nuvb-20241007.xsd (EX-101.SCH) — 4KB
- nuvb-20241007_def.xml (EX-101.DEF) — 13KB
- nuvb-20241007_lab.xml (EX-101.LAB) — 22KB
- nuvb-20241007_pre.xml (EX-101.PRE) — 14KB
- d787897d8k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NUVATION BIO INC. Date: October 7, 2024 By: /s/ David Hung Name: David Hung Title: Chief Executive Officer